• Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease 

      MARTIN-CARDONA, ALBERT; Horta, D.; Florez-Diez, P.; Vela, M.; Mesonero, F.; Ramos Belinchón, C.; García, M.J.; Masnou, H.; de la Peña Negro, Luisa Carmen; SUAREZ FERRER, CRISTINA; Casanova, M.J.; Ortiz Durán, M.; Peña, E.; Calvet, X.; Fernández-Prada, S.J.; Gonzalez-Muñoza, Carlos; Piqueras, M.; Rodríguez-Lago, I.; Sainz, E.; Bas-Cutrina, Francesc; Mancediño Marcos, N.; Ojeda, A.; Orts, B.; Sicilia, B.; Castaño García, A.; Domènech, E.; Esteve, M. (Digestive and Liver Disease, 2024-03)
      Background and aims: Hepatitis C virus (HCV) management in Inflammatory Bowel Disease (IBD) is uncertain. The ECCO guidelines 2021 recommended HCV treatment but warn about the risk of IBD reactivation. ...
    • Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA 

      Gargallo, Carla J.; Ricart Gomez, Elena; Iglesias, Eva; de Francisco, Ruth; Gisbert, Javier Pérez; Taxonera, Carlos; Mañosa, Miriam; Aguas, Mariam; Navarrete-Muñoz, Eva María; Sanahuja Martínez, Ana; Guardiola, Jordi; Mesonero, Francisco; Rivero, Montserrat; BARRIO, JESÚS; Vera Mendoza, Isabel; De Castro Parga, María Luisa; García-Planella, Esther; Calvet, Xavier; Martín Arranz, María Dolores; García, Santiago; Sicilia, Beatriz; Carpio, Daniel; DOMENECH, EUGENI; Gomollón, Fernando (Clinical Gastroenterology and Hepatology, 2024-11)
      Background & Aims: The impact of patient sex on the presentation of inflammatory bowel disease (IBD) has been poorly evaluated. Our aims were to assess potential disparities in IBD phenotype and progression ...